A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Immunity, Cellular, Drug Therapy, Combination, CD4-Positive T-Lymphocytes, Antigens, Anti-HIV Agents, Viral Load, tucaresol
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are at least 18 years old. Are HIV-positive. Have more than 300 CD4 T cells/microL at screening. Are taking certain anti-HIV drugs. Have been taking these anti-HIV drugs successfully for at least 6 months. Do not expect to change their anti-HIV therapy while they are in the study. Have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy. Have viral load that cannot be detected at screening and baseline tests. Are able to complete weekly visits. Exclusion Criteria Patients will not be eligible for this study if they: Cannot give informed consent. Have abnormal laboratory test results at baseline. Are pregnant or breast-feeding. Have had certain short-term or long-term illnesses (such as heart disease, sickle cell disease, anemia, or lung problems). Have received a vaccination within the 30 days prior to enrollment. Have received any other experimental drug within 60 days of enrollment. Are taking abacavir (Ziagen, GW1592) or drugs that affect the immune system, such as IL-2, GM-CSF, corticosteroids, or cyclosporine. Have a history of tumors. Are actively using illegal drugs (methadone is allowed). Have hepatitis B or hepatitis C.
Sites / Locations
- Rockefeller Univ